S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

$1.25
-0.01 (-0.79%)
(As of 10:10 AM ET)
Today's Range
$1.25
$1.26
50-Day Range
$1.15
$1.37
52-Week Range
$0.57
$1.70
Volume
1,423 shs
Average Volume
315,674 shs
Market Capitalization
$56.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

AVROBIO MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
58.7% Upside
$2.00 Price Target
Short Interest
Healthy
0.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of AVROBIO in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.58 to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

646th out of 939 stocks

Biological Products, Except Diagnostic Industry

111th out of 156 stocks

AVRO stock logo

About AVROBIO Stock (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock Price History

AVRO Stock News Headlines

AVROBIO Inc.
AVRO Apr 2024 2.500 call
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
AVRO May 2024 2.500 call
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
AVROBIO and Tectonic Therapeutic Announce Merger
Mizuho Downgrades AVROBIO (AVRO)
Avrobio just downgraded at Mizuho, here's why
Avrobio Inc AVRO
AVROBIO, Inc. (AVRO)
Avrobio (AVRO) Gets a Buy from Barclays
See More Headlines
Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+58.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$12.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.29 per share
Book Value
$2.13 per share

Miscellaneous

Free Float
40,734,000
Market Cap
$56.52 million
Optionable
Optionable
Beta
1.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Erik John Ostrowski M.B.A. (Age 52)
    President, Interim CEO, CFO & Treasurer
    Comp: $1.25M
  • Dr. Azadeh Golipour Ph.D. (Age 44)
    Chief Technology Officer
    Comp: $1.01M
  • Dr. Essra Ridha FFPM (Age 41)
    M.D., Chief Medical Officer
    Comp: $1.12M
  • Mr. Jeffrey Medin Ph.D.
    Scientific Founder
  • Mr. Steven N. Avruch J.D. (Age 62)
    Chief Legal Officer & Secretary
    Comp: $506.68k
  • Mr. Scott Gottesman
    Vice President of Human Resource
  • Ms. Kirsten Dupuis
    Chief of Staff

AVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares.
View AVRO analyst ratings
or view top-rated stocks.

What is AVROBIO's stock price target for 2024?

2 analysts have issued twelve-month target prices for AVROBIO's stock. Their AVRO share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price.
View analysts price targets for AVRO
or view top-rated stocks among Wall Street analysts.

How have AVRO shares performed in 2024?

AVROBIO's stock was trading at $1.36 at the beginning of the year. Since then, AVRO stock has decreased by 7.4% and is now trading at $1.26.
View the best growth stocks for 2024 here
.

When is AVROBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AVRO earnings forecast
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.75).

What other stocks do shareholders of AVROBIO own?
When did AVROBIO IPO?

AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (6.13%), Vanguard Group Inc. (3.59%), Vanguard Group Inc. (3.59%), Vazirani Asset Management LLC (1.46%), FNY Investment Advisers LLC (0.90%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.79%).
View institutional ownership trends
.

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVRO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners